Mount Sinai researchers uncovered a mechanism that tumor cells exploit selective autophagy for metabolic reprogramming that benefits tumor cell growth and offers resistance to glucose deprivation. The study suggests that AKAP220-mediated autophagy as a novel therapeutic target for specific cancer treatment.